Literature DB >> 25542906

Biomarkers of kidney injury and klotho in patients with atherosclerotic renovascular disease.

Moo Yong Park1, Sandra M Herrmann2, Ahmed Saad2, Alfonso Eirin2, Hui Tang2, Amir Lerman3, Stephen C Textor2, Lilach O Lerman4.   

Abstract

BACKGROUND AND OBJECTIVES: Occlusive renovascular disease and hypertension may progress to CKD. Circulating levels of several biomarkers, including fibroblast growth factor (FGF)-23, Klotho, and soluble urokinase plasminogen activator receptor (suPAR), are altered in patients with CKD, but their role in essential hypertension (EH) and renovascular hypertension (RVH) remains unclear. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Levels of FGF-23, Klotho, suPAR, plasminogen activator inhibitor (PAI)-1, tissue factor, and tissue factor pathway inhibitor (TFI) were measured in the inferior vena cava and renal vein of hypertensive patients with atherosclerotic renal artery stenosis (n=12) or age-matched participants with EH (n=12) and relatively preserved renal function. Single-kidney blood flow was measured to calculate renal release of markers. For control, peripheral vein levels were measured in healthy volunteers (HVs; n=12).
RESULTS: FGF-23 levels did not differ among the groups, whereas Klotho levels were lower in participants with RVH and EH than in HVs, and suPAR levels were elevated in patients with RVH compared with HVs and patients with EH (6.1±1.5 versus 4.4±1.9 and 3.2±1.2 ng/ml, P<0.05). PAI-1 levels were higher in patients with RVH than in patients with EH, but tissue factor and TFI levels were not statistically significantly different. After adjustment for GFR, Klotho levels remained decreased in both RVH and EH, and suPAR and PAI-1 levels remained elevated in RVH. eGFR correlated inversely with systemic and renal vein suPAR levels, and directly with systemic Klotho levels.
CONCLUSIONS: Klotho levels are low in hypertensive patients, whereas suPAR and PAI-1 levels are specifically elevated in RVH, correlating with GFR. Klotho, PAI-1, and suPAR may be markers of kidney injury in hypertensive patients.
Copyright © 2015 by the American Society of Nephrology.

Entities:  

Keywords:  biomarkers; kidney injury; renovascular hypertension

Mesh:

Substances:

Year:  2014        PMID: 25542906      PMCID: PMC4348686          DOI: 10.2215/CJN.07290714

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  50 in total

1.  Inflammatory and injury signals released from the post-stenotic human kidney.

Authors:  Alfonso Eirin; Monika L Gloviczki; Hui Tang; Mario Gössl; Kyra L Jordan; John R Woollard; Amir Lerman; Joseph P Grande; Stephen C Textor; Lilach O Lerman
Journal:  Eur Heart J       Date:  2012-07-06       Impact factor: 29.983

2.  Circulating α-klotho levels in CKD and relationship to progression.

Authors:  Hyoung Rae Kim; Bo Young Nam; Dong Wook Kim; Min Woong Kang; Jae-Hyun Han; Mi Jung Lee; Dong Ho Shin; Fa Mee Doh; Hyang Mo Koo; Kwang Il Ko; Chan Ho Kim; Hyung Jung Oh; Tae-Hyun Yoo; Shin-Wook Kang; Dae Suk Han; Seung Hyeok Han
Journal:  Am J Kidney Dis       Date:  2013-03-27       Impact factor: 8.860

3.  Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.

Authors:  Changli Wei; Shafic El Hindi; Jing Li; Alessia Fornoni; Nelson Goes; Junichiro Sageshima; Dony Maiguel; S Ananth Karumanchi; Hui-Kim Yap; Moin Saleem; Qingyin Zhang; Boris Nikolic; Abanti Chaudhuri; Pirouz Daftarian; Eduardo Salido; Armando Torres; Moro Salifu; Minnie M Sarwal; Franz Schaefer; Christian Morath; Vedat Schwenger; Martin Zeier; Vineet Gupta; David Roth; Maria Pia Rastaldi; George Burke; Phillip Ruiz; Jochen Reiser
Journal:  Nat Med       Date:  2011-07-31       Impact factor: 53.440

Review 4.  VEGF-initiated angiogenesis and the uPA/uPAR system.

Authors:  Johannes M Breuss; Pavel Uhrin
Journal:  Cell Adh Migr       Date:  2012-10-17       Impact factor: 3.405

5.  Stent revascularization restores cortical blood flow and reverses tissue hypoxia in atherosclerotic renal artery stenosis but fails to reverse inflammatory pathways or glomerular filtration rate.

Authors:  Ahmed Saad; Sandra M S Herrmann; John Crane; James F Glockner; Michael A McKusick; Sanjay Misra; Alfonso Eirin; Behzad Ebrahimi; Lilach O Lerman; Stephen C Textor
Journal:  Circ Cardiovasc Interv       Date:  2013-07-30       Impact factor: 6.546

6.  Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.

Authors:  Ivana Pavik; Philippe Jaeger; Lena Ebner; Carsten A Wagner; Katja Petzold; Daniela Spichtig; Diane Poster; Rudolf P Wüthrich; Stefan Russmann; Andreas L Serra
Journal:  Nephrol Dial Transplant       Date:  2012-11-04       Impact factor: 5.992

7.  The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients.

Authors:  Krystyna Pawlak; Michal Mysliwiec; Dariusz Pawlak
Journal:  Thromb Res       Date:  2007-11-28       Impact factor: 3.944

8.  Circulating suPAR in two cohorts of primary FSGS.

Authors:  Changli Wei; Howard Trachtman; Jing Li; Chuanhui Dong; Aaron L Friedman; Jennifer J Gassman; June L McMahan; Milena Radeva; Karsten M Heil; Agnes Trautmann; Ali Anarat; Sevinc Emre; Gian M Ghiggeri; Fatih Ozaltin; Dieter Haffner; Debbie S Gipson; Frederick Kaskel; Dagmar-Christiane Fischer; Franz Schaefer; Jochen Reiser
Journal:  J Am Soc Nephrol       Date:  2012-11-08       Impact factor: 10.121

9.  Stenting and medical therapy for atherosclerotic renal-artery stenosis.

Authors:  Christopher J Cooper; Timothy P Murphy; Donald E Cutlip; Kenneth Jamerson; William Henrich; Diane M Reid; David J Cohen; Alan H Matsumoto; Michael Steffes; Michael R Jaff; Martin R Prince; Eldrin F Lewis; Katherine R Tuttle; Joseph I Shapiro; John H Rundback; Joseph M Massaro; Ralph B D'Agostino; Lance D Dworkin
Journal:  N Engl J Med       Date:  2013-11-18       Impact factor: 91.245

10.  Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor.

Authors:  Cristina Zanchi; Monica Locatelli; Ariela Benigni; Daniela Corna; Susanna Tomasoni; Daniela Rottoli; Flavio Gaspari; Giuseppe Remuzzi; Carlamaria Zoja
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

View more
  16 in total

1.  Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) and CKD Progression in Children.

Authors:  Darcy K Weidemann; Alison G Abraham; Jennifer L Roem; Susan L Furth; Bradley A Warady
Journal:  Am J Kidney Dis       Date:  2020-01-24       Impact factor: 8.860

2.  Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children.

Authors:  Franz Schaefer; Howard Trachtman; Elke Wühl; Marietta Kirchner; Salim S Hayek; Ali Anarat; Ali Duzova; Sevgi Mir; Dusan Paripovic; Alev Yilmaz; Francesca Lugani; Klaus Arbeiter; Mieczyslaw Litwin; Jun Oh; Maria Chiara Matteucci; Jutta Gellermann; Simone Wygoda; Augustina Jankauskiene; Günter Klaus; Jiri Dusek; Sara Testa; Aleksandra Zurowska; Alberto Caldas Afonso; Melissa Tracy; Changli Wei; Sanja Sever; William Smoyer; Jochen Reiser
Journal:  JAMA Pediatr       Date:  2017-11-06       Impact factor: 16.193

Review 3.  Potential application of klotho in human chronic kidney disease.

Authors:  Javier A Neyra; Ming Chang Hu
Journal:  Bone       Date:  2017-01-20       Impact factor: 4.398

4.  Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.

Authors:  Ayman Samman Tahhan; Salim S Hayek; Pratik Sandesara; Jamal Hajjari; Muhammad Hammadah; Wesley T O'Neal; Heval M Kelli; Ayman Alkhoder; Nima Ghasemzadeh; Yi-An Ko; Hiroshi Aida; Mohamad Mazen Gafeer; Naser Abdelhadi; Kareem Hosny Mohammed; Keyur Patel; Shipra Arya; Jochen Reiser; Viola Vaccarino; Laurence Sperling; Arshed Quyyumi
Journal:  Atherosclerosis       Date:  2017-06-08       Impact factor: 5.162

5.  Cellular Senescence: A New Player in Kidney Injury.

Authors:  Yongxin Li; Lilach O Lerman
Journal:  Hypertension       Date:  2020-08-31       Impact factor: 10.190

6.  Clinic significance of markedly decreased α-klothoin women with preeclampsia.

Authors:  Cuifang Fan; Yueqiao Wang; Jingyi Wang; Di Lei; Yanmei Sun; Sicong Lei; Min Hu; Yatao Tian; Rui Li; Suqing Wang
Journal:  Am J Transl Res       Date:  2016-05-15       Impact factor: 4.060

Review 7.  αKlotho and Chronic Kidney Disease.

Authors:  J A Neyra; M C Hu
Journal:  Vitam Horm       Date:  2016-03-24       Impact factor: 3.421

Review 8.  Novel therapeutic approaches for chronic kidney disease due to glomerular disorders.

Authors:  Maria Del Nogal-Avila; Hector Donoro-Blazquez; Manish K Saha; Caroline B Marshall; Lionel C Clement; Camille E A Macé; Sumant S Chugh
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-04

Review 9.  Klotho/FGF23 Axis in Chronic Kidney Disease and Cardiovascular Disease.

Authors:  Xiang Lu; Ming Chang Hu
Journal:  Kidney Dis (Basel)       Date:  2016-11-17

Review 10.  Klotho in Clinical Nephrology: Diagnostic and Therapeutic Implications.

Authors:  Javier A Neyra; Ming Chang Hu; Orson W Moe
Journal:  Clin J Am Soc Nephrol       Date:  2020-07-22       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.